A bill for an act relating to the standards of practice relating to the prescribing of certain pain medications.
Impact
If enacted, HSB160 will amend the current standards established by the Iowa Board of Medicine. Physicians will be required to document in the patient’s medical record that they have discussed this crucial information with the patient. This regulation aims to enhance patient awareness and safety regarding the use of potentially addictive medications, thereby seeking to combat the opioid crisis by ensuring patients are better informed about the risks involved.
Summary
House Study Bill 160 addresses the standards of practice for physicians when prescribing certain pain medications, specifically controlled substances such as opioid pain relievers. The bill mandates that prior to issuing an initial prescription of these medications for either acute or chronic pain, and again before the third prescription in the same treatment plan, the physician must have a discussion with the patient or their guardian. This discussion is to cover essential topics such as the risks of addiction, the necessity of the prescription, alternative treatments available, and the potential dangers associated with opioid use.
Contention
The bill could lead to discussions around the sufficiency of the current standards for pain management and whether additional regulations may create barriers for patients in legitimate pain. Supporters may argue that it encourages responsible prescribing practices and prioritizes patient safety. However, opponents may express concerns that such requirements could complicate the prescribing process and hinder access to necessary pain relief for patients with genuine medical needs.
A bill for an act relating to the requirements for a prescribing psychologist or a psychologist with a conditional prescription certificate.(See SF 133.)
A bill for an act relating to the requirements for a prescribing psychologist or a psychologist with a conditional prescription certificate.(See HF 183.)
Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.